To improve the vector platform for use in targeted gene therapy against GBM, we have refined the technology by replacing the CMV promoter with the tumor‐specific Grp78 promoter and designed the dual tumor targeting RGD4C/AAVP‐Grp78 vector (Kia et al, 2012, 2013). This evidence concerns the gene HSPA5 and neoplasm.